Table 2 Comparison of postoperative chemotherapy between the UFS and NAC groups
Postoperative chemotherapy | Total (n = 131) | UFS (n = 64) | NAC (n = 67) | NAC (GS) (n = 62) | P value* (UFS v.s. NAC) | P value* (UFS v.s. NAC (GS)) |
|---|---|---|---|---|---|---|
Gemcitabine (monotherapy or combination therapy) | 80 | 39 | 41 | 36 | 0.855 | 1.000 |
S-1 (monotherapy or combination therapy) | 93 | 45 | 48 | 45 | 0.692 | 0.681 |
CDDP plus gemcitabine or S-1 | 6 | 6 | 0 | 0 | 0.013 | 0.028 |
Erlotinib plus gemcitabine | 2 | 2 | 0 | 0 | 0.244 | 0.496 |
Paclitaxel (monotherapy) | 1 | 1 | 0 | 0 | 1.000 | 0.496 |
GS | 7 | 4 | 3 | 3 | 0.718 | 1.000 |
GnP | 40 | 14 | 26 | 23 | 0.035 | 0.051 |
FOLFIRINOX | 12 | 2 | 10 | 10 | 0.030 | 0.014 |